Led by BioN­Tech, six biotechs line up for Oc­to­ber IPOs

Oc­to­ber: The sea­son of swirling red leaves, Jack-o-lanterns, post­sea­son base­ball and this year, a fresh har­vest of six biotech IPOs ripe with clin­i­cal-stage drugs, try­ing to raise a com­bined $817 mil­lion next week.

All of the com­pa­nies have ear­marked a sub­stan­tial por­tion of the ex­pect­ed pro­ceeds to clin­i­cal work, push­ing such ther­a­pies as mR­NA for melanoma, inebi­lizum­ab for NMOSD, and an­ti­bod­ies for blood can­cer and sol­id tu­mors clos­er to tri­als.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.